Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue Sarcoma
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Efficacy and safety of trabectedin in real-life practice, routinely used for the management
of advanced sarcoma after failure of anthracyclines and ifosfamide or patients unsuited to
receive these drugs in Germany.
Trabectedin is indicated for the treatment of patients with advanced soft tissue sarcoma,
after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents.
Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.